Luigi Argentino Apr 24, 2022:

@Laura Come dice un personaggio abbastanza noto "mi sono fatto pirsuaso". I fully agree. Buona domenica

Laura Gentili Apr 23, 2022:

Non necesssariamente. Vedi ad esempio: Patients with COPD generally present with highly heterogeneous measures of disease severity and
disease activity.4,5 The progressive decline in lung function in patients with COPD is associated with
significant morbidity and mortality. Approved medical treatments for COPD are targeted primarily to
the relief of respiratory symptoms and the prevention and reduction of COPD exacerbations.
Reductions in the number or severity of exacerbations or an impact on mortality are both of high
interest for organizations developing novel candidate COPD therapies. However, the efficient use of
these important clinical endpoints can present a number of challenges. For studies that specify
exacerbations and/or mortality as key outcomes, it is important that the study population be composed
of subjects who are likely to have the event(s) of interest during the duration of the trial. Currently,
selection of subjects for inclusion in such studies relies primarily on clinical characteristics (e.g.,
subjects with respiratory symptoms and/or a prior history of COPD exacerbations), yet in most clinical
trials of COPD patients, there is evidence that 50%–60% of enrol

Luigi Argentino Apr 23, 2022:

(sulle terapie) contro le riacutizzazioni? Ciao Laura, ritengo che il significato della tua risposta non centri bene l'obiettivo dello studio. Secondo me, lo studio non è sulle riacutizzazion ma è sui trattamenti terapeutici (già adottati o da adottare) CONTRO le riacutizzazioni. Si tratta, ripeto, di una mia personale interpretazione supportata dal ragionamento che gli tudi clinici in genere, riguardano i trattamenti contro determinate patologie (o il loro esacerbarsi). Che ne pensi?